Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas

Eijun Itakura, Hidetaka Yamamoto, Yoshinao Oda, Masazumi Tsuneyoshi

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Background: Angiosarcomas are malignant mesenchymal neoplasms, including sarcomas of presumptive vascular endothelial origin and sarcomas of probable lymphatic origin. It is, however, often difficult to determine whether they are from blood vascular or lymphatic endothelium. The majority of angiosarcomas are thought to originate from vascular endothelia and spread via bloodstream to lung, but lymphatic metastases can occur. Methods: We investigated immunohistochemical expression of vascular endothelial growth factors (VEGF-A, VEGF-C) and their receptors (VEGFR-1, VEGFR-2, VEGFR-3) in a series of 34 angiosarcomas. Results: VEGF-A was expressed by 32/34 (94%), VEGF-C by 4/34 (12%), VEGFR-1 by 32/34 (94%), VEGFR-2 by 22/34 (65%), and VEGFR-3 by 27/34 (79%). Patients who expressed low or no VEGFR-2 showed a significantly unfavorable prognosis by log-rank test (P = 0.010) and multivariate analysis (hazard ratio, 5.16; 95% CI, 1.40-19.04; P = 0.014). VEGFR-1 and VEGFR-3 were not significantly associated with patients' prognosis. Conclusions: VEGF-A and VEGFR-1 were detected in diverse subtypes of angiosarcomas. In cooperation, VEGF-A and VEGF-C are likely to be involved in the development of angiosarcoma associated with lymphedema. VEGF-C expression may cause susceptibility to lymphatic metastasis through tumor lymphangiogenesis. Angiosarcoma of the scalp, which is traditionally considered as a true hemangiosarcoma, may include some cases of lymphatic origin.

Original languageEnglish
Pages (from-to)74-81
Number of pages8
JournalJournal of Surgical Oncology
Volume97
Issue number1
DOIs
Publication statusPublished - Jan 1 2008

Fingerprint

Hemangiosarcoma
Vascular Endothelial Growth Factor Receptor
Vascular Endothelial Growth Factor C
Vascular Endothelial Growth Factor Receptor-1
Vascular Endothelial Growth Factor Receptor-3
Vascular Endothelial Growth Factor Receptor-2
Vascular Endothelial Growth Factor A
Lymphatic Metastasis
Vascular Endothelium
Vascular Endothelial Growth Factors
Lymphatic Endothelium
Lymphangiogenesis
Lymphedema
Scalp
Sarcoma
Non-Hodgkin's Lymphoma
Blood Vessels
Neoplasms
Multivariate Analysis
Lung

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. / Itakura, Eijun; Yamamoto, Hidetaka; Oda, Yoshinao; Tsuneyoshi, Masazumi.

In: Journal of Surgical Oncology, Vol. 97, No. 1, 01.01.2008, p. 74-81.

Research output: Contribution to journalArticle

@article{19db1b1f0c28429c9847d5c3adaecfb0,
title = "Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas",
abstract = "Background: Angiosarcomas are malignant mesenchymal neoplasms, including sarcomas of presumptive vascular endothelial origin and sarcomas of probable lymphatic origin. It is, however, often difficult to determine whether they are from blood vascular or lymphatic endothelium. The majority of angiosarcomas are thought to originate from vascular endothelia and spread via bloodstream to lung, but lymphatic metastases can occur. Methods: We investigated immunohistochemical expression of vascular endothelial growth factors (VEGF-A, VEGF-C) and their receptors (VEGFR-1, VEGFR-2, VEGFR-3) in a series of 34 angiosarcomas. Results: VEGF-A was expressed by 32/34 (94{\%}), VEGF-C by 4/34 (12{\%}), VEGFR-1 by 32/34 (94{\%}), VEGFR-2 by 22/34 (65{\%}), and VEGFR-3 by 27/34 (79{\%}). Patients who expressed low or no VEGFR-2 showed a significantly unfavorable prognosis by log-rank test (P = 0.010) and multivariate analysis (hazard ratio, 5.16; 95{\%} CI, 1.40-19.04; P = 0.014). VEGFR-1 and VEGFR-3 were not significantly associated with patients' prognosis. Conclusions: VEGF-A and VEGFR-1 were detected in diverse subtypes of angiosarcomas. In cooperation, VEGF-A and VEGF-C are likely to be involved in the development of angiosarcoma associated with lymphedema. VEGF-C expression may cause susceptibility to lymphatic metastasis through tumor lymphangiogenesis. Angiosarcoma of the scalp, which is traditionally considered as a true hemangiosarcoma, may include some cases of lymphatic origin.",
author = "Eijun Itakura and Hidetaka Yamamoto and Yoshinao Oda and Masazumi Tsuneyoshi",
year = "2008",
month = "1",
day = "1",
doi = "10.1002/jso.20766",
language = "English",
volume = "97",
pages = "74--81",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas

AU - Itakura, Eijun

AU - Yamamoto, Hidetaka

AU - Oda, Yoshinao

AU - Tsuneyoshi, Masazumi

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Background: Angiosarcomas are malignant mesenchymal neoplasms, including sarcomas of presumptive vascular endothelial origin and sarcomas of probable lymphatic origin. It is, however, often difficult to determine whether they are from blood vascular or lymphatic endothelium. The majority of angiosarcomas are thought to originate from vascular endothelia and spread via bloodstream to lung, but lymphatic metastases can occur. Methods: We investigated immunohistochemical expression of vascular endothelial growth factors (VEGF-A, VEGF-C) and their receptors (VEGFR-1, VEGFR-2, VEGFR-3) in a series of 34 angiosarcomas. Results: VEGF-A was expressed by 32/34 (94%), VEGF-C by 4/34 (12%), VEGFR-1 by 32/34 (94%), VEGFR-2 by 22/34 (65%), and VEGFR-3 by 27/34 (79%). Patients who expressed low or no VEGFR-2 showed a significantly unfavorable prognosis by log-rank test (P = 0.010) and multivariate analysis (hazard ratio, 5.16; 95% CI, 1.40-19.04; P = 0.014). VEGFR-1 and VEGFR-3 were not significantly associated with patients' prognosis. Conclusions: VEGF-A and VEGFR-1 were detected in diverse subtypes of angiosarcomas. In cooperation, VEGF-A and VEGF-C are likely to be involved in the development of angiosarcoma associated with lymphedema. VEGF-C expression may cause susceptibility to lymphatic metastasis through tumor lymphangiogenesis. Angiosarcoma of the scalp, which is traditionally considered as a true hemangiosarcoma, may include some cases of lymphatic origin.

AB - Background: Angiosarcomas are malignant mesenchymal neoplasms, including sarcomas of presumptive vascular endothelial origin and sarcomas of probable lymphatic origin. It is, however, often difficult to determine whether they are from blood vascular or lymphatic endothelium. The majority of angiosarcomas are thought to originate from vascular endothelia and spread via bloodstream to lung, but lymphatic metastases can occur. Methods: We investigated immunohistochemical expression of vascular endothelial growth factors (VEGF-A, VEGF-C) and their receptors (VEGFR-1, VEGFR-2, VEGFR-3) in a series of 34 angiosarcomas. Results: VEGF-A was expressed by 32/34 (94%), VEGF-C by 4/34 (12%), VEGFR-1 by 32/34 (94%), VEGFR-2 by 22/34 (65%), and VEGFR-3 by 27/34 (79%). Patients who expressed low or no VEGFR-2 showed a significantly unfavorable prognosis by log-rank test (P = 0.010) and multivariate analysis (hazard ratio, 5.16; 95% CI, 1.40-19.04; P = 0.014). VEGFR-1 and VEGFR-3 were not significantly associated with patients' prognosis. Conclusions: VEGF-A and VEGFR-1 were detected in diverse subtypes of angiosarcomas. In cooperation, VEGF-A and VEGF-C are likely to be involved in the development of angiosarcoma associated with lymphedema. VEGF-C expression may cause susceptibility to lymphatic metastasis through tumor lymphangiogenesis. Angiosarcoma of the scalp, which is traditionally considered as a true hemangiosarcoma, may include some cases of lymphatic origin.

UR - http://www.scopus.com/inward/record.url?scp=38149060090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149060090&partnerID=8YFLogxK

U2 - 10.1002/jso.20766

DO - 10.1002/jso.20766

M3 - Article

C2 - 18041747

AN - SCOPUS:38149060090

VL - 97

SP - 74

EP - 81

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 1

ER -